Collectively, our data demonstrate that the IL-17E/IL-17RB pathway contributes to TNBC resistance to EGFR therapeutics through a loop that amplifies and sustains the phosphorylation of the main EGFR downstream kinases implicated in tumor resistance. Here, EGFR is linked to neoplasm.